Orphan Australia: News

15 Jul 09	S.L.A. Pharma and Orphan Australia Announce Licensing Agreement for Metronidazole Ointment.
08 Nov 08	CellSeed and Orphan Australia Announce Licensing Agreement for the Regenerated Oral Mucosal Epithelial Cell-sheet for Limbal Stem Cell Deficiency of Cornea epithelium.
21 Aug 08	Once Daily dosing for Salofalk tablets and granules
01 Apr 08	Orphan Australia launches ACTIQ (fentanyl citrate lozenges) PBS listed from 1st April 2008
16 Oct 07	Professor Gunnar Birgegard - Anagrelide and Myeloproliferative Disorders
03 Nov 05	IV Busulfex™ Receives Orphan Designation In Australia
09 Mar 05	AMP Capital purchases stake in Orphan Australia
14 Jul 04	Remodulin® (treprostinil sodium) Injection Approved for Marketing in Australia for Pulmonary Arterial Hypertension
30 Sep 03	Ferriprox® (deferiprone) Tablets: PBS Listing Recommended for 1 February 2004
02 Apr 03	Ferriprox® (deferiprone) Tablets Approved for Marketing in Australia for the Treatment of iron-overload in Thalassaemia Major
06 Jun 02	GUILFORD ANNOUNCES MARKETING AND DISTRIBUTION AGREEMENT FOR GLIADEL® IMPLANTS
22 May 01	FERRIPROX™ RECEIVES ORPHAN DRUG DESIGNATION IN AUSTRALIA
12 Jun 01	Cephalon Announces Marketing and Distribution Agreement For ACTIQ® in Australia and New Zealand
01 Oct 00	Ursofalk® (ursodeoxycholic acid) available on PBS for Primary Biliary Cirrhosis from November 1st 2000